FdaApplication
NDA 215192
Identifiers
- fda_app_no: NDA215192
Properties
| Property | Value |
|---|---|
| applicant_name | AKEBIA THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2024-03-27 |
Revenue by product
VAFSEO
| Period | Revenue |
|---|---|
| Q2 2026 | $21.3M |
| Q1 2026 | $15.8M |
| Q4 2025 | $6.2M |
| Q3 2025 | $14.3M |
| Q2 2025 | $13.3M |
| Q1 2025 | $12.0M |
| Q4 2024 | $0.0M |
| Q3 2024 | $0.0M |
| Q2 2024 | $0.0M |
| Q1 2024 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VAFSEO | VADADUSTAT | 450MG | TABLET;ORAL |
| VAFSEO | VADADUSTAT | 150MG | TABLET;ORAL |
| VAFSEO | VADADUSTAT | 300MG | TABLET;ORAL |
3 products